Recherche Fr menu fr ClientConnect
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
    Référence: 20220801
    Date de publication: 13 mars 2024

    Promoteur – Intermédiaire Financier




    The operation is a quasi-equity financing to Novadip, an innovative Belgian biotech developing therapies for rare genetic diseases in the field of critical size bone defects, bone non-union and other bone related diseases.

    Additionality and Impact

    The Operation contributes to the InvestEU objective of research, development and innovation. The purpose of the loan is to provide direct, equity-type financing under EIB's Venture Debt Instrument to support research, development and innovation activities of the innovative company 'Novadip', a clinical-stage biopharmaceutical company based in Belgium. The financing of this project addresses the failure in financial markets for RDI, arising from limited access to commensurate financing as a result of factors such as information asymmetries, misalignment of incentives, etc. Novadip is a biopharmaceutical company focused on the development of advanced therapies for bone-related diseases. By creating knowledge externalities, the project is expected to provide significant socio-economic benefits, will strengthen Belgium and Europe's position in the field of advanced therapies, and it will help to create and retain skilled staff engaged in the Company's RDI activities. Thanks to the support of InvestEU, the EIB may provide long term financing in the form of venture debt to a highly innovative but high-risk early-stage company with no access to commercial debt. By contributing to extending the cash runway and therefore to de-risking the development plan of the company, the innovative EIB financing is expected to crowd-in third party investors (such as Venture Capitals, Strategic Investors, Private Equity players, etc.) and allow the company to accelerate its development and forming strategic alliances. The project would not have been carried out (to the same extent) by the EIB without the InvestEU support.


    The project concerns the development of therapeutic solutions for patients suffering from critical size bone defects, including Congenital Pseudarthrosis of the Tibia (CPT), a rare and highly debilitating paediatric disease, and other bone-related conditions that can severely impact patient's quality of life and can result in amputation.


    Montant BEI envisagé (montant approximatif)

    EUR 18 million

    Coût total (montant approximatif)

    EUR 60 million

    Aspects environnementaux

    The promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.

    Passation des marchés

    The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The EIB's services will verify details during the project due diligence.


    Signé - 19/07/2023

    À l'examen
    7 juin 2023
    19 juillet 2023

    Clause de non-responsabilité

    Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
    Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).

    Mots-clés correspondants

    Belgique Industrie